Fourteen months ago IQVIA and Veeva resolved an eight-year legal fight. On October 13 the two companies announced that IQVIA has selected Veeva CTMS, eTMF, Study Startup and Site Connect as enterprise standard applications across its clinical development studies. The speed of that turn is the story. IQVIA was not a buyer short of options, since it sells clinical technology of its own, and it spent from 2017 to 2025 in litigation with the company whose software now runs its trial operations. Standardizing the operations layer for a business with roughly 94,000 employees in more than 100 countries is a statement about where this category has settled.
The more useful detail is what IQVIA did not standardize. The announcement covers trial management, essential documents, study startup and site communication. Richard Staub, president of Research and Development Solutions at IQVIA, was pointed about customers keeping their choice of EDC, RTSM and eCOA, including IQVIA’s own capabilities. That is the negotiated border of this deal. IQVIA has selected the clinical operations and document layer, where Veeva is strongest, and held onto flexibility in data capture, where it still sells competing products. Read the two halves together and this looks like each side keeping the ground it can defend.
For research sites, the question that matters is whether this reduces the number of systems they are asked to learn. Site Connect is the piece aimed at that problem, and making it standard across a clinical development business this large would mean a meaningful number of investigators working in the same interface on IQVIA-run studies instead of a different portal for each sponsor. The announcement extends an EDC partnership the two companies struck in August 2025, when IQVIA joined Veeva’s CRO Clinical Data Partner program as part of a settlement that dismissed all claims and counterclaims with no damages paid by either side.
Watch the scope. Enterprise standard is doing a lot of work in this announcement, and it matters a great deal whether it governs new studies only or extends to migrating an existing book of trials, because the second is a multi-year program with real site-facing disruption along the way. The announcement does not say which. Both will be at the Veeva R&D and Quality Summit in Boston on October 20 and 21, which is the first obvious place for that answer to surface.
Source link: https://www.veeva.com/newsroom/iqvia-selects-veeva-clinical-operations-applications/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
